New immune approach tested in fight against ALS
NCT ID NCT02059759
Summary
This study tested whether adding a low-dose immune drug called Interleukin-2 to standard ALS medication (riluzole) is safe and affects the immune system. It involved 36 adults with ALS who received either the drug or a placebo in three short courses over 12 weeks. The main goal was to see how the drug changed specific immune cells and to check for side effects, helping decide if it should be tested in larger trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.